LoginRegister

    Glenmark gets USFDA nod for Aprepitant capsules

    Written by Ruby Khatun Khatun   |  
    Glenmark gets USFDA nod for Aprepitant capsules

    New Delhi: Glenmark Pharmaceuticals said its US-based arm has received final approval from the US FDA for Aprepitant capsules, used for preventing nausea caused by cancer chemotherapy.


    Glenmark Pharmaceuticals Inc, USA, has received final approval by the United States Food & Drug Administration (USFDA) for Aprepitant capsules USP, 40 mg, 80 mg, and 125 mg, the company said in a regulatory filing.


    The tablets are generic versions of Merck Sharp & Dohme Corporation's Emend capsules, it added.

    According to IMS Health sales data for the 12 months ended August, Emend Capsules, 40 mg, 80 mg, and 125 mg achieved annual sales of around USD 64.9 million, Glenmark said.

    The company's current portfolio consists of 127 products authorized for distribution in the US marketplace and 60 abbreviated new drug applications (ANDAs) which are pending approval with the USFDA, it added.

    abbreviated new drug applicationsapprovalAprepitant capsulescancerchemotherapyEmend capsulesgeneric versionsGlenmarkGlenmark PharmaGlenmark Pharmaceuticalsindian pharma newsMercknauseapharma newspharma news indiaUSFDA
    Source : PTI

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Ruby Khatun Khatun
    Ruby Khatun Khatun
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X